Edwards Lifesciences Investor update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Welcome, everyone, and thank you for being here. Before I turn it over to Bernard to make some opening remarks, please take a moment to familiarize yourself with our cautionary statement. You guys all know this. It's an important slide behind me. During today's event, we may be making forward-looking statements, and it is possible our actual results can differ from our expectations. Here's the agenda for today's session. We'll spend the first 20 minutes on TMTT, discussing the results of the CLASP IITR, and then we will move to TAVR and talk more about the long-awaited results of the PROGRESS trial. We are very privileged to have the physicians with us here today, so please try as you might to focus the questions on the trial's results and what the physicians will focus on.
With that, I'll turn it over to Bernard for a few opening remarks.
Good evening, everyone, and thanks for being here. It is obviously a very exciting day for Edwards, and more importantly, for the many patients we serve and the many patients who are going to benefit from the result of today in tricuspid and TAVR. I like to always start with a quick reminder that this is truly a result of our unique innovation strategy as a company. We are committed to bringing a breakthrough innovation across the portfolio, TAVR, mitral, tricuspid, and we are also laying the foundation for AR and structural heart failure later, but also our commitment to world-class evidence. That's not easy to do that. It takes courage, years of investment, years of belief, having a vision.
I want also to recognize our field organization, which is very unique at Edwards, where every day, they take care of patients, one patient at a time, to make sure that physician can have the best patient outcome. At the end of the day, when Edwards lead, everyone benefit. The patient receive the best therapy, great outcome. Physician have access to breakthrough technologies. In many of the cases, even like today, we are enabling the change of practice and evolving medicine, but also providing economic benefit to the entire healthcare ecosystem. So I'm very proud about what we do, what the 17,000 employees across Edwards are doing, ensuring this kind of impact. Let me now introduce the first session. The first session will be focusing on one therapy, PASCAL, in our TMTT portfolio. What we are going to talk about is mainly about CLASP IITR.
A little bit also, Charlie Davidson will be able to talk about that, but also Ted, about TRIC-I-HF, which is also a study that has been presented a little bit earlier this year. Important data for tricuspid patients. We are joined by Charlie Davidson. He is the Chief of Cardiology and Medical Director of the Bluhm Cardiovascular Institute. He is deeply involved in trial leadership across TMTT portfolio for many years, including serving as the global co-PI of the CLASP IITR trial. Also on stage with me, please, Devin, Ted, and Dr. Davidson, please join me. Also on stage with me is Devin Chopra, our leader of the TMTT business. Devin joined us about eight years ago and has deep expertise in med tech and at the company. He has overseen the TMTT success over the last several years as we have introduced the portfolio.
Finally, someone that everybody knows, Dr. Ted Feldman, he is our Senior Vice President of Medical Affairs of TMTT. Ted has been the brain behind many of our clinical evidence initiatives. Before Edwards, he has been a pioneer, a global leader, a researcher, and innovator. Again, thanks for the panelists here, and I am going to turn to Charlie for a quick overview of the data, and then we will take questions. Charlie, back to you. Thank you, Bernard.
My pleasure. Thanks for having me here this evening. I am just going to take you through a few of these slides. Many of you probably were at the presentation today, so you have already seen this. This is not Oh, sorry. Let me go back here. You already saw the whole presentation. Can you get me back to the first slide? Thank you. There we go. Okay, so this is the presentation that Suzanne and I made earlier today. So I am going to bring you right to the primary endpoint, which was a six-month analysis. The study was started in 2020. The first patient was enrolled right the month that COVID started, in March, and it was originally designed to be a two-year endpoint on this trial. Through the course of first four years, it stayed that way as people then became other devices approved.
We had TTVR approved, EVOQUE. We had TriClip approved, and what we found was there was attrition in the control group, and that started in October 2024, when FDA approval came for that. At that point, it was moved back to a one-year endpoint. Following that, a year later, we had CMS approval for coverage for those devices, and there was further attrition and went back to a six-month endpoint. So, we are presenting six-month data here. We have one-year data that we presented. You saw that today. These patients are going to be followed annually out to five years. There will be more data to come behind this. But just to understand how we got to the evolution of a six-month endpoint. The six-month endpoint was a composite endpoint of mortality, RVAD or heart transplant, tricuspid valve intervention, number of heart failure hospitalizations, and KCCQ improvement.
This is fairly similar to what you've seen in other tricuspid trials, in TRISCEND II, TRILUMINATE. TRIC-I-HF, which I'll speak to later, is slightly different. What you're seeing here, the main driver of the endpoint, as again, as is in almost all these trials, is the marked improvement in KCCQ, which I'll get into a little more detail here. In this trial, there was also some attrition. Remember, this is at 6 months, so this is before we started seeing attrition from the control group to a treatment arm. With all of that, the main win ratio was 1.98.
That means that people are twice as likely to get the benefit of this device, that if they received that compared to optimal medical therapy, and optimal medical therapy in this trial included things like SGLT2 inhibitors, which were not routinely used in some of the earlier tricuspid trials. So, better medical therapy in this trial than what we've seen. TRIC-I-HF, again, I'll speak to, also had very good medical therapy. Going to move to the next slide, and this is basically showing the KCCQ improvement. As you can see here, 57% of those that received the device had a large to moderate improvement, whereas 25% of those that stayed in the control group got worse. Remember, the control group included people that moved over, and we had 20 patients that moved from the control group to a attrition to a treatment arm.
They stay in the control group in the analysis, because if we do it by a modified intention-to-treat analysis, they're still counted in the control group even though they've been treated. With that, there still is 25% that got worse, and with this, we had 57% that got better. The conclusions from this trial, and then I'm happy to answer a lot of questions, is it met its 6-month primary endpoint, demonstrated superiority of the system with medical therapy compared to medical therapy alone, in patients that had severe or greater tricuspid regurgitation, and that was primarily driven by KCCQ and somewhat by TDI. There was no difference in mortality or heart failure hospitalization between the two groups. Also, I'm more than happy to speak to mortality. It was not significantly different.
Why you saw a very low mortality rate in this trial, which in the control group, which was 4%, is interesting that we've not seen in any of the tricuspid trials to date. Some of that, I think, is due to medical therapy, but there's also that attrition in the TDI group in this population that accounts for that. The treatment in the PASCAL system resulted in significant TR reduction, 80% of patients achieving less than or equal to moderate TR at 1 year, compared to 30% in the control group, which was significant. There was substantial improvement in patient-reported healthcare outcomes, fully evident by 30 days, and really was persisted out to 1 year. This trial demonstrates the safety and efficacy of the PASCAL system to improve health status in symptomatic patients with TR.
I can tell you, as someone that has been treating patients with TR for now 8 or 9 years with different devices, I can tell you the number one thing that people want is to feel better. We want to have them live longer, do not get me wrong. A 6-month trial is no way powered to determine a mortality difference. I think the enrichment that we saw from TRIC-I-HF, which I want to get into here, is a trial that would really look at hard endpoints. That is one of the things we have been lacking in the tricuspid trials, is to show that we can impact heart failure hospitalization and potentially mortality. What Jörg Hausleiter did, a good friend and colleague, which was really a brilliant design, was he took and enhanced the patients that were enrolled in the trial.
Remember, we have taken all comers that are symptomatic with severe TR. He took particularly patients that had cardiorenal, so they had impaired kidney disease, CKD, and had TR, or they had a hepatorenal, so they had evidence of hepatic dysfunction and had severe TR, or they had a previous heart failure hospitalization. What he also did was to allow these people that once they presented for their next heart failure hospitalization, to then get treated. So, it was really a terrific design to really enhance outcomes and enhance, excuse me, events to show hard outcome differences. What he did and show this was that he was able to show a difference in death and heart failure hospitalizations, as you can see in panel A. Panel C shows freedom from hospitalization for heart failure. I think this was a very important trial.
Now, I think they followed out the 3 years, which is another piece of this. They do not have complete 3-year follow-up at this point, but at least there was a suggestion there that there is a potential mortality benefit. When you think about going back to some of the other trials, those of you who are familiar with the COAPT trial, that was a trial that was done in people with functional mitral regurgitation, and it randomized medical therapy to edge-to-edge repair for mitral valve disease. That trial did not get positive for a hard endpoint of mortality until 3 years. If that trial had stopped at 1 year or 2 year, we would still be sitting here not treating patients with FMR with devices. So, I think we need more of this if we really want hard endpoints.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
